#United States #San Francisco #Verana Health #Oncology Datasets #Urologic Cancer

Verana Health Launches Comprehensive Urologic Oncology Datasets

In a significant advancement for cancer research, Verana Health has announced the introduction of state-of-the-art end-to-end datasets specifically designed for urologic oncology. This initiative aims to enhance research into bladder and prostate cancer treatments, promising to deliver crucial insights into disease detection, therapy efficacy, and patient outcomes.

The launch of these datasets is notably timed with the upcoming American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium taking place in San Francisco from February 26-28, 2026, which is expected to draw nearly 6,000 attendees keen to discuss the latest innovations in urological cancer care.

Patients suffering from genitourinary cancers often navigate a complex healthcare pathway that begins with urology and radiation oncology specialists. As their condition evolves, they may transfer to other medical professionals, such as medical oncologists. However, this patient journey is marked by significant information gaps that can hinder the understanding of treatment decisions, biomarker application, and real-world outcomes. Such gaps present challenges for life sciences organizations aiming to understand treatment sequences and improve clinical development processes.

Verana Health operates as the exclusive data and analytics partner for the American Urological Association (AUA) Quality (AQUA)® Registry. The company specializes in converting unstructured electronic health record data into high-quality, research-ready datasets through advanced AI and large language model techniques. The new bladder and prostate datasets are the result of a recent merger with COTA, dramatically expanding Verana’s access to over 30 academic medical centers and more than 10 million oncology patients. This merger has allowed the integration of longitudinal data across various specialties, offering unparalleled insights into patient journeys and supporting evidence generation for regulatory and market access purposes.

Sujay Jadhav, CEO of Verana Health, expressed enthusiasm about the potential of these new datasets: "Following the COTA merger, we're able to provide life sciences organizations with a holistic view of the patient journey, capturing the complexities of urological cancer care. We are excited to offer these initial datasets to researchers dedicated to enhancing treatment options and patient outcomes."

The bladder cancer dataset aims to provide real-world therapeutic insights by detailing rapidly evolving treatment approaches for both muscle-invasive and non-muscle-invasive bladder cancers. This includes critical metrics such as tumor stage, focality, grade, and patient response to treatments. On the other hand, the prostate cancer dataset is designed to track the transition of care among urology, radiation oncology, and medical oncology settings, facilitating a comprehensive understanding of the disease's progression, including hormone-sensitive, hormone-resistant, and metastatic states.

Dr. CK Wang, General Manager of Oncology and Chief Medical Officer at Verana Health, highlighted the urgency for research and development in urological cancers, citing an increase in diagnoses as a major driver for this initiative: "The rising incidence of bladder and prostate cancers underlines the importance of understanding treatment outcomes based on longitudinal real-world data and the demands placed upon life sciences organizations."

For those interested in exploring these urological cancer datasets further, opportunities are available to meet with Verana Health representatives during the ASCO Genitourinary Cancers Symposium.

About Verana Health

Verana Health, Inc. is a pioneering digital health company focused on transforming patient care and clinical research through the application of artificial intelligence and physician expertise. By leveraging extensive access to the world's largest patient data sources in oncology, ophthalmology, neurology, and urology, Verana Health enhances real-world evidence creation. This supports healthcare providers in improving care quality and empowers life sciences companies to expedite new therapy development. For more information, visit Verana Health.